Sickle Cell Disease (SCD): Clinical Trials

5 trials for Sickle Cell Disease (SCD), newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 recruiting, 1 terminated. 5 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 25Completed 3, Recruiting 1, Terminated 1
Phase 31Recruiting 1

Follow Sickle Cell Disease (SCD): new trials by email Literature Review of Sickle Cell Disease (SCD) trials Research Report on Sickle Cell Disease (SCD)

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia
Pharmacokinetic based dosage change, Pharmacokinetic dosing - Sickle Cell Disease (SCD)
Phase 2 / Phase 3RecruitingYves Pastore292026-02-032026-08-21
Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease
ALXN1820 - Sickle Cell Disease (SCD)
Phase 2TerminatedAlexion Pharmaceuticals, Inc.22023-02-222025-01-13
Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease
Crizanlizuamb, Standard of Care - Sickle Cell Disease (SCD)
Phase 2CompletedNovartis Pharmaceuticals582019-12-102024-10-09
Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients
Crizanlizumab - Sickle Cell Disease (SCD)
Phase 2CompletedNovartis Pharmaceuticals1172018-10-012025-10-16
Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)
crizanlizumab - Sickle Cell Disease (SCD)
Phase 2CompletedNovartis Pharmaceuticals572017-12-192024-10-09

Narrower conditions

Anemia, Sickle Cell (5)  ·  Albuminuria (1)  ·  COVID-19 (1)  ·  Hemoglobin SC Disease (1)  ·  Renal Insufficiency, Chronic (1)  ·  Vaso-Occlusive Crises (1)

Broader conditions

Anemia (5)  ·  Anemia, Hemolytic (5)  ·  Anemia, Hemolytic, Congenital (5)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5)  ·  Genetic Diseases, Inborn (5)  ·  Hematologic Diseases (5)  ·  Hemic and Lymphatic Diseases (5)  ·  Hemoglobinopathies (5)  ·  Chronic Disease (1)  ·  Coronaviridae Infections (1)  ·  Coronavirus Infections (1)  ·  Disease Attributes (1)  ·  Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)  ·  Infections (1)

Interventions

crizanlizumab (2)  ·  Standard of Care (1)

Sponsors

Novartis Pharmaceuticals (3)  ·  Alexion Pharmaceuticals, Inc. (1)  ·  Yves Pastore (1)

Countries

United States (4)  ·  Brazil (2)  ·  Canada (2)  ·  France (2)  ·  Lebanon (2)  ·  Spain (2)  ·  Turkey (Türkiye) (2)  ·  United Kingdom (2)  ·  Belgium (1)  ·  Colombia (1)  ·  Germany (1)  ·  Greece (1)  ·  India (1)  ·  Ireland (1)  ·  Italy (1)

Results publications

PMID 34922648, PMID 36355805, PMID 36529836, PMID 37254256, PMID 39497751, PMID 40569673

NIH funding

2017 (1), 2018 (1)